Hanmi Science Co

Hanmi Science Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Hanmi Science Co (008930.KS) as of Oct 10, 2026 is 105.20. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 39.43 — a change of 166.77% (higher).

P/FCF

105.20

YoY

166.77%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Hanmi Science Co is 2025 105.20 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Hanmi Science Co was 2024 39.43 . It decreases by 166.77% higher compared to the previous year.

The Hanmi Science Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
1,456.40 KRW
Jan 1, 2019
239.02 KRW
Jan 1, 2020
218.79 KRW
Jan 1, 2021
236.94 KRW
Jan 1, 2022
2,536.27 KRW
Jan 1, 2023
106.25 KRW
Jan 1, 2024
39.43 KRW
Jan 1, 2025
105.20 KRW
The Hanmi Science Co P/FCF history
YEARP/FCFYoY
105.20+166.77%
39.43-62.89%
106.25-95.81%
2,536.27+970.41%
236.94+8.30%
218.79-8.46%
239.02-83.59%
1,456.40-1,957.83%
-78.39-296.42%
39.91-40.00%
66.52-88.39%
573.05—
Access this data via the Eulerpool API

Hanmi Science Co Stock analysis

What does Hanmi Science Co do? Hanmi Science Co Ltd is a South Korean company specializing in the manufacturing of pharmaceutical products, biologics, and medical devices. The company was founded in 1973 as a chemical company and obtained the license for drug manufacturing in 1990, expanding its product range to include pharmaceuticals. Today, the company's business model includes three main areas: research and development, manufacturing and sales of drugs, and sales of medical devices. Hanmi aims to develop and produce innovative and high-quality products to improve people's health worldwide. In the field of research and development, Hanmi Science is a leading company. It specializes in the research and development of novel drugs and biologics. The company has an impressive track record in the development and marketing of innovative drugs for the treatment of diabetes, cancer, and rare diseases. This includes a range of biosimilars produced using biotechnological methods that are more affordable compared to original medical substances. Hanmi also has a state-of-the-art production infrastructure that meets the highest quality standards and ensures reliable supply. In the field of drug manufacturing, the company produces generics and biosimilars that are sold in more than 50 countries worldwide. Hanmi also specializes in the production of chemotherapeutics and parenteral drugs that have proven efficacy and safety. The medical device sales division focuses on marketing high-quality medical devices, including diagnostic and monitoring devices used in the medical field. Hanmi also distributes a range of medical consumables, including transfusion sets, syringes, infusion sets, and catheters. Hanmi Science Co Ltd offers a wide range of products that can be categorized into various categories. Among the pharmaceutical products are antidiabetic drugs, anticancer agents, antidepressants, antibiotics, antiviral medications, and products for the treatment of rare diseases. The portfolio also includes biosimilars of botulinum toxin, insulin, and humiderm among the biologics. Overall, Hanmi Science Co Ltd holds a strong position in the South Korean market and has also established a good reputation internationally. With its focus on research and development and the production of high-quality drugs and medical devices, the company has a promising future. Hanmi Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hanmi Science Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Hanmi Science Co is 105.20 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Hanmi Science Co changed from 39.43 to 105.20, representing a 166.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Hanmi Science Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Hanmi Science Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Hanmi Science Co

All Key Metrics — Hanmi Science Co